Biocybernetics

eureKARE launches inaugural eureKAWARDS to support European synthetic biology innovation

Retrieved on: 
Wednesday, July 28, 2021
Articles, Life sciences, Biology, Bioinformatics, Biotechnology, Appropriate technology, Biocybernetics, Synthetic biology, Synbio, Synthetic

The winner will receive free access to eureKAREs synthetic biology studio, eureKASYNBIO, for one year.

Key Points: 
  • The winner will receive free access to eureKAREs synthetic biology studio, eureKASYNBIO, for one year.
  • The winner will also receive guidance and support from eureKAREs team and broad network of validated academic and industrial professionals in synthetic biology.
  • Rodolphe Besserve, Chief Executive Officer of eureKARE, echoed: The first eureKAWARDS is an exceptional opportunity for researchers across Europe to showcase their ideas as part of an event looking to celebrate and support synthetic biology.
  • eureKARE is a unique project development company dedicated to investing and developing next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology.

Asensus Surgical Announces 510(k) Submission to FDA for Machine Vision Capabilities Expansion

Retrieved on: 
Wednesday, July 14, 2021
Data management, Health, FDA, Medical devices, Technology, Surgery, Pharmaceutical, Intelligence, Articles, Biocybernetics, Cybernetics, Intelligence amplification, Transhumanism, Technology, Academic disciplines

The expansion of augmented intelligence capabilities is the next driver of performance in digital surgery, said Anthony Fernando, Asensus Surgical President and CEO.

Key Points: 
  • The expansion of augmented intelligence capabilities is the next driver of performance in digital surgery, said Anthony Fernando, Asensus Surgical President and CEO.
  • This submission is an important milestone in our continued leadership with machine vision and augmented intelligence in surgery.
  • We believe these new capabilities will support surgical planning, decision support and teaching.
  • This press release includes statements relating to the Senhance Surgical System and our 510(k) submission to FDA for machine vision capabilities expansion.

eureKARE launches with $60 million to build and finance next generation biotech companies in Europe

Retrieved on: 
Tuesday, May 18, 2021
Articles, Branches of biology, Biology, Molecular genetics, Appropriate technology, Biocybernetics, Biotechnology, Synthetic biology, Screening

It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year.

Key Points: 
  • It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year.
  • eureKARE aims to build bridges between these two bodies to create and support new ventures.
  • The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology).
  • Stellate is also evaluating a portfolio of new drug candidates in other conditions, with capabilities across discovery, screening, production and diagnostic development.\n'

eureKARE launches with $60 million to build and finance next generation biotech companies in Europe

Retrieved on: 
Tuesday, May 18, 2021
Articles, Branches of biology, Biology, Molecular genetics, Appropriate technology, Biocybernetics, Biotechnology, Synthetic biology, Screening

It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year.

Key Points: 
  • It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year.
  • eureKARE aims to build bridges between these two bodies to create and support new ventures.
  • The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology).
  • Stellate is also evaluating a portfolio of new drug candidates in other conditions, with capabilities across discovery, screening, production and diagnostic development.\n'

Twist Bioscience Supports the Engineering Biology Research Consortium as it Publishes Statement of Ethics

Retrieved on: 
Thursday, May 13, 2021
Technology, General Health, Science, Genetics, Veterinary, Agriculture, Natural Resources, Biotechnology, Health, Other Science, Research, Other Technology, Nanotechnology, Other Health, Pharmaceutical, Stem cells, Oncology, Articles, Emerging technologies, Branches of biology, Biology, Genetic engineering, Synthetic biology, Appropriate technology, Biocybernetics, Synthetic Genomics, Genomics, Twist Bioscience

b'Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its support of the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research .

Key Points: 
  • b'Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its support of the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research .
  • As with many other rapidly growing and highly impactful technologies, the long-term implications of this innovative research require forward-thinking guidelines and ethical frameworks to support responsible use.
  • The EBRC Statement of Ethics helps to provide additional guidance to our community, which we welcome and support.\xe2\x80\x9d\nTwist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.\nThis press release contains forward-looking statements.

$13.86 Billion Synthetic Biology Market, 2026 - Market to Grow at a CAGR of Approx 36% - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 29, 2021
Research, Science, Articles, Branches of biology, Life sciences, Appropriate technology, Biocybernetics, Biotechnology, Synthetic biology, Vaccine

This will help to stabilize global medicine prices and increases and the demand for synthetic biology market in the medical sector.\nGlobally, cancer is the second leading cause of death which is responsible for an estimated 9.6 million deaths in 2020.

Key Points: 
  • This will help to stabilize global medicine prices and increases and the demand for synthetic biology market in the medical sector.\nGlobally, cancer is the second leading cause of death which is responsible for an estimated 9.6 million deaths in 2020.
  • According to World Health Organization, about 1 in 6 deaths are due to cancer.
  • But, rising demand for bio-fuels, and investments on synthetic drugs and vaccines would further offer profitable growth chances in the market.\nIn order to create larger functional architecture by synthetic biology, device modularization and standardization become a necessity.
  • BioAcrylic from OPXBIO also will reduce oil-dependence and offer more stable prices.\n'

Provectus Algae Appoints CEO of Senti Biosciences to Board to Aid Advancement of High-Throughput Synthetic Biology Platform

Retrieved on: 
Tuesday, March 23, 2021
Biotechnology, Health, Other Natural Resources, Food, Beverage, Agriculture, Other Science, Natural Resources, Research, Retail, Genetics, Science, Articles, Branches of biology, Life sciences, Biocybernetics, Bioinformatics, Biotechnology, Synthetic biology, Systems biology

Dr. Lu is co-founder and CEO of therapeutics and synthetic biology company Senti Biosciences .

Key Points: 
  • Dr. Lu is co-founder and CEO of therapeutics and synthetic biology company Senti Biosciences .
  • Dr. Lu brings essential expertise in computer programming, electrical engineering and synthetic biology to the company, having pioneered these technologies at Massachusetts Institute of Technology (M.I.T.)
  • We couldn't be more excited to welcome him onto our board, said Provectus CEO and Founder Nusqe Spanton.
  • Tims proven track record in the field of synthetic biology and computational biology will enable us to unlock the potential of our platform more quickly.

Global $14.12 Billion Synthetic Biology in Agriculture and Food Markets to 2025: Rapid Technology Advancements and Inclination Toward Bio-Based Products

Retrieved on: 
Monday, March 15, 2021
Articles, Life sciences, Academic disciplines, Biotechnology, Emerging technologies, Biocybernetics, Bioinformatics, Synthetic biology, Systems biology, Food security, Agriculture, Food

The global synthetic biology in agriculture and food market is projected to grow from $3.20 billion in 2020 to $14.12 billion by 2025, at a CAGR 34.56% from 2020 to 2025.

Key Points: 
  • The global synthetic biology in agriculture and food market is projected to grow from $3.20 billion in 2020 to $14.12 billion by 2025, at a CAGR 34.56% from 2020 to 2025.
  • The growth in synthetic biology in agriculture and food market is expected to be driven by the increasing need for global food security, increasing consumer awareness about high nutritional food, and rising capital investments for synthetic biology research.
  • Synthetic biology has garnered the attention of industries, such as agriculture and food industry.
  • The global synthetic biology in agriculture and food market holds a prominent share in various countries of North America and Europe.

Synthetic Biology in Agriculture and Food Market - Global Market Analysis 2020-2025 with Focus on Product, Technology, Application, Industry, Country, Patent, Government Programs and Funding - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021
Other Science, Science, Articles, Life sciences, Academic disciplines, Biotechnology, Emerging technologies, Food industry, Agronomy, Biocybernetics, Synthetic biology, Agriculture, Food security, Food

The "Synthetic Biology in Agriculture and Food Market - A Global Market and Regional Analysis: Focus on Product, Technology, Application, Industry, Country, Patent, Government Programs and Funding - Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Synthetic Biology in Agriculture and Food Market - A Global Market and Regional Analysis: Focus on Product, Technology, Application, Industry, Country, Patent, Government Programs and Funding - Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The growth in synthetic biology in agriculture and food market is expected to be driven by the increasing need for global food security, increasing consumer awareness about high nutritional food, and rising capital investments for synthetic biology research.
  • Synthetic biology has garnered the attention of industries, such as agriculture and food industry.
  • The global synthetic biology in agriculture and food market holds a prominent share in various countries of North America and Europe.

Synthetic Biology Market by Application (Healthcare, Industrial, Food and Agriculture, and Others) and Geography (Asia, Europe, North America, and ROW) - Global Forecast to 2024

Retrieved on: 
Monday, February 1, 2021
Biotechnology, Health, Genetics, Science, Research, Articles, Philosophy, Branches of philosophy, Appropriate technology, Biocybernetics, Biotechnology, Synthetic biology, Market analysis, Analysis

View the full release here: https://www.businesswire.com/news/home/20210201005481/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210201005481/en/
    Technavio has announced its latest market research report titled Global Synthetic Biology Market 2020-2024 (Graphic: Business Wire)
    Worried about the impact of COVID-19 on your Business?
  • The report on the synthetic biology market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The synthetic biology market analysis includes the Application segment and Geography Landscape.
  • This study identifies the increasing demand for synthetic genes & synthetic cells as one of the prime reasons driving the synthetic biology market growth during the next few years.